Health Care·Biotechnology·$3.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.19 | N/A | -46.15% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.19 | N/A | -46.15% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about the current financial performance. They did not provide specific guidance for future quarters.
Management did not provide specific insights into revenue expectations.
The company acknowledged challenges in meeting earnings expectations.
ACADIA Pharmaceuticals reported a larger-than-expected loss per share, which contributed to a 5.2% drop in stock price. The lack of revenue details and guidance may raise concerns among investors about the company's future performance. Overall, the market reacted negatively, reflecting uncertainty about the company's direction.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AMERICAN INTL GROUP
May 5, 2014